Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin Clinical Trials in New York, New York

1 recruitingNew York, New York

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Other Locations

Rochester, Minnesota1

Showing 1–1 of 1 trials

Recruiting

Phase 1Phase 2

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more

TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
Partnerships
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

Data provided by ClinicalTrials.gov & ANZCTR